Citations

Clear

181 citation(s) found for "Good, J".

Good’s Syndrome: Thymoma with Acquired Immunodeficiency
Koo, Chi Wan , Lo, Ying‐Chun

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 18, 2023 | Volume: 208 | Issue: 3 | Pages: 322-324

10.1164/rccm.202211-2159im | PMID 37071872 Get It

Is YouTube a Good Resource for Laparoscopic Adrenalectomy Education Content?
Orton, Taylor S., Eldredge, Richard S, Hangge, Patrick T., Wasif, Nabil , Stucky, Chee-Chee H, Eldredge, R Scott , Deshpande, Anagha , Stucky, Chee‐Chee , Cronin, Patricia A

Mayo Clinic

Journal of the American College of Surgeons | April 17, 2023 | Volume: 236 | Issue: 5 | Pages: S26-S26

10.1097/01.xcs.0000932468.42395.f5 Get It

Abstract 727: Early detection saves lives: I survived, and you can too— Any day above ground is a good day
Merriweather, AJ, Fullwood, Dottington , Crook, Jennifer , Asto-Flores, Emelina , Fathi, Parisa , Dronca, Roxana , Pressey, Shannon, Ngufor, Che

Mayo Clinic

Cancer Research | April 5, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 727-727

10.1158/1538-7445.am2023-727 Get It

Abstract The day I received news of my prostate cancer diagnosis time paused for a minute. My heart was heavy, and my mind racing and my soul appeared to leave my body as the physician kept talking. I’m looking at this doctor and having internal conversations with myself about dying. My attention switched from listening to reflecting to Fred Sanford holding his heart and saying “Elizabeth, I am coming to join you”, but my wife was right next to me holding my hand. The embrace of our interlocked fingers without saying a word to one another assured both of us this too shall pass. My knowing I had support encouraged me to begin educating myself about the science of survivorship. The presence of prostate cancer resources was absent in my community. I began reading information online to grasp a better understanding of this disease. The information gained encouraged me to request a second opinion from another oncologist. I was amaze by the difference in opinion about treatment options. I felt the urge to identify and specifically speak with other Black men going through this process. Everywhere I looked for support groups felt like removing my hands from pocket and watching lent flee from my fingers. What did I do? I registered my own prostate cancer support group with the state of Florida. The group grew from a few to 20 Black men across major metropolitan cities in Florida. These group meetings extended to men leading groups in their communities. I joined the Prostate Health Education Network as the Regional Ambassador to promote prostate awareness and clinical trials. My advocacy presence in the state of Florida led to Dr. Odedina and I crossing paths to champion elimination of prostate cancer health disparities for Black men. I am a Citizen Scientist in the lab of Dr. Odedina working on the inclusive cancer care and research equity for Black men consortium. I have co-authored publications, co-presented at conferences, served on research projects, and contributed to grant funding totaling over $25 million as a citizen scientist. Currently working on a Department of Defense funded grant focusing on the point of prostate cancer diagnosis. The project has completed several events to dispel myths about participation in clinical research while discussions about early detection is vital to improve survivorship. The reward from this work is knowing I am helping create spaces for Black men never to travel this journey alone. I believe men appreciate having a patient supporter but require fellowship with men who have traveled the road to gain navigational insights on how to maneuver across this terrain. Citation Format: AJ Merriweather, Dottington Fullwood, Che Ngufor, Jennifer Crook, Emelina Asto-Flores, Parisa Fathi, Roxana Dronca, Shannon Pressey, Folakemi Odedina. Early detection saves lives: I survived, and you can too— Any day above ground is a good day [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 727.
Abstract OT1-15-01: SWOG 1904: Cluster-randomized controlled trial of patient and provider decision support to increase chemoprevention informed choice among women with atypical hyperplasia or lobular carcinoma in situ (MiCHOICE)
Arnold, Kathryn B. , Stieb, Andrew, Amenta, Jacquelyn , Law, Cynthia, Sandoval-Leon, Ana, King, Tari A. , Mangino, Debra A. , Pruthi, Sandhya , Perdekamp, Maria Grosse , Braun‐Inglis, Christa , Krisher, Stacy, Yee, Lisa, Bertoni, Danielle M., Seaward, Samantha A. , Wisinski, Kari B. , Floyd, Justin D., Zarwan, Corrine, VanderWalde, Lindi, Ross, Masey M., Steen, Preston D. , Lo, Shelly S. , Conlin, Alison, Yost, Kathleen J. , Ellerton, John , Lin, Erin, Sardesai, Sagar , Jernigan, Cheryl, Arun, Banu, Sardesai, Sagar , Seaward, Samantha A , Crew, Katherine D. , Anderson, Garnet L. , Sandoval-Leon, Ana Cristina , Colonna, Sarah V. , Yee, Lisa, Ballinger, Tarah Jean , Ross, Masey, Pederson, Holly J. , Hershman, Dawn L. , Neuhouser, Marian L. , Kukafka, Rita

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: OT1-15-01-OT1-15-01

10.1158/1538-7445.sabcs22-ot1-15-01 Get It

Abstract Background: Despite evidence of substantial breast cancer risk reduction, few high-risk women adopt chemopreventive medications such as selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs). Women with benign breast disease, such as atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS), have an increased risk of developing breast cancer and derive a greater benefit from antiestrogens compared to other high-risk women. Reasons for low uptake of chemoprevention include insufficient patient and clinician knowledge about antiestrogens, time constraints during the clinical encounter, and concerns about side effects. To address these barriers, we have developed patient and provider web-based decision support tools to improve informed choice about breast cancer chemoprevention among women with AH or LCIS. Study design: We are conducting a cluster-randomized controlled trial of clinical decision support to improve chemoprevention informed choice among women with AH or LCIS and their treating providers. Twenty-six U.S. sites through the SWOG Cancer Research Network were randomly assigned 1:1 to standard educational materials alone or in combination with the patient-centered decision aid (RealRisks) and provider decision support tool (BNAV). A total of 415 patients and 200 healthcare providers will be recruited from these sites. RealRisks consists of interactive modules to calculate personalized breast cancer risk and elicit preferences on chemoprevention. The modules are available in English and Spanish. BNAV is comprised of self-directed case-based learning modules on breast cancer risk assessment and chemoprevention. Patients complete questionnaires at baseline, 6 and 12 months. Providers complete surveys at baseline and after their enrolled patient’s 6-month clinical encounter. The primary endpoint is chemoprevention informed choice at 6 months, using a measure combining knowledge, attitude, and intention scales. Secondary endpoints include perceived breast cancer risk/worry, chemoprevention knowledge/intention, decision conflict/regret, shared decision-making, and chemoprevention uptake. For patients who begin chemoprevention, adherence and reasons for discontinuation are assessed annually for up to 5 years. Barriers and facilitators to implementing RealRisks and BNAV into clinic workflow will be assessed by conducting patient and provider interviews at baseline and mid-implementation. Eligibility criteria: Eligible patients include women, age 35-74 years, with AH or LCIS, no history of breast cancer, no prior use of SERMs or AIs, no bilateral mastectomies, English or Spanish-speaking, and access to the internet. Eligible providers include breast surgeons, medical oncologists, primary care providers, and physician extenders who see patients with AH or LCIS. Statistical methods: We have 90% power to detect a 15% increase in the frequency of chemoprevention informed choice with a 1-sided 0.025 level test, assuming an intraclass correlation (ICC) of 0.02 to account for clustering, roughly equal accrual at each site, 10% loss to follow-up, and ≤10% event rate in the control arm. Current/target accrual: The trial was activated on 9/1/2020. As of 7/7/2022, all 26 sites have been randomized, 157/200 providers and 184/415 patients have been enrolled. Discussion: Our hybrid effectiveness/implementation study seeks to evaluate the effectiveness of a multi-level intervention in promoting informed decision-making about breast cancer chemoprevention. Study results will provide valuable insights on how the decision support tools are integrated in diverse clinical settings. Citation Format: Katherine D. Crew, Garnet Anderson, Kathryn Arnold, Andrew Stieb, Jacquelyn N. Amenta, Cynthia Law, Ana Sandoval-Leon, Sarah Colonna, Tari King, Debra Mangino, Sandhya Pruthi, Maria Grosse Perdekamp, Christa Braun-Inglis, Stacy Krisher, Lisa Yee, Danielle Bertoni, Samantha Seaward, Kari B. Wisinski, Justin Floyd, Corrine Zarwan, Tarah J. Ballinger, Lindi VanderWalde, Masey M. Ross, Preston Steen, Shelly Lo, Alison Conlin, Kathleen Yost, John Ellerton, Erin Lin, Holly J. Pederson, Sagar Sardesai, Cheryl Jernigan, Dawn Hershman, Marian L. Neuhouser, Banu K. Arun, Rita Kukafka. SWOG 1904: Cluster-randomized controlled trial of patient and provider decision support to increase chemoprevention informed choice among women with atypical hyperplasia or lobular carcinoma in situ (MiCHOICE) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT1-15-01.
Management of Anticoagulation/Antiplatelet Medication and Venous Thromboembolism Prophylaxis in Elective Spine Surgery: Concise Clinical Recommendations Based on a Modified Delphi Process
Berven, Sigurd, Streiff, Michael B. , Buchanan, Ian A. , Ha, Alex , Bonfield, Christopher M. , Buchholz, Avery L., Burch, Shane , Devin, Clinton J. , Dimar, John R. , Good, Christopher R. , Lombardi, Joseph M. , Mandigo, Christopher E. , Bydon, Mohamad , Oppenlander, Mark E., Poulter, Gregory T., Shah, Suken A. , Singh, Kern , Than, Khoi D. , Spyropoulos, Alex C. , Kaatz, Scott , Schutzer, Richard, Wang, Tina Z. , Mazique, Derek C., Lenke, Lawrence G. , Lehman, Ronald A. , Zuckerman, Scott L. , Kerolus, Mena G. , Buchowski, Jacob M. , Gum, Jeffrey L. , Kim, Han Jo , Kim, Jun , Polly, David W. , Jain, Amit

Mayo Clinic

Spine | February 2, 2023 | Volume: 48 | Issue: 5 | Pages: 301-309

10.1097/brs.0000000000004540 | PMID 36730667 Get It

Study Design. Delphi method. Objective. To gain consensus on the following questions: (1) When should anticoagulation/antiplatelet (AC/AP) medication be stopped before elective spine surgery?; (2) When should AC/AP medication be restarted after elective spine surgery?; (3) When, how, and in whom should venous thromboembolism (VTE) chemoprophylaxis be started after elective spinal surgery? Summary of Background Data. VTE can lead to significant morbidity after adult spine surgery, yet postoperative VTE prophylaxis practices vary considerably. The management of preoperative AC/AP medication is similarly heterogeneous. Materials and Methods. Delphi method of consensus development consisting of three rounds (January 26, 2021, to June 21, 2021). Results. Twenty-one spine surgeons were invited, and 20 surgeons completed all rounds of questioning. Consensus (>70% agreement) was achieved in 26/27 items. Group consensus stated that preoperative Direct Oral Anticoagulants should be stopped two days before surgery, warfarin stopped five days before surgery, and all remaining AC/AP medication and aspirin should be stopped seven days before surgery. For restarting AC/AP medication postoperatively, consensus was achieved for low-risk/medium-risk/high-risk patients in 5/5 risk factors (VTE history/cardiac/ambulation status/anterior approach/operation). The low/medium/high thresholds were POD7/POD5/POD2, respectively. For VTE chemoprophylaxis, consensus was achieved for low-risk/medium-risk/high-risk patients in 12/13 risk factors (age/BMI/VTE history/cardiac/cancer/hormone therapy/operation/anterior approach/staged separate days/staged same days/operative time/transfusion). The one area that did not gain consensus was same-day staged surgery. The low-threshold/medium-threshold/high-threshold ranges were postoperative day 5 (POD5) or none/POD3-4/POD1-2, respectively. Additional VTE chemoprophylaxis considerations that gained consensus were POD1 defined as the morning after surgery regardless of operating finishing time, enoxaparin as the medication of choice, and standardized, rather than weight-based, dose given once per day. Conclusions. In the first known Delphi study to address anticoagulation/antiplatelet recommendations for elective spine surgery (preoperatively and postoperatively); our Delphi consensus recommendations from 20 spine surgeons achieved consensus on 26/27 items. These results will potentially help standardize the management of preoperative AC/AP medication and VTE chemoprophylaxis after adult elective spine surgery.
Never Let Me Go: “Almost Dead” Isn’t Good Enough
Clarke, Michelle J.

Mayo Clinic

The American Journal of Bioethics | January 22, 2023 | Volume: 23 | Issue: 2 | Pages: 60-61

10.1080/15265161.2022.2159586 | PMID 36681921 Get It

627. Too Much of a Good Thing? The Clinical Effects of Very High Serum Posaconazole Levels
Jannetto, Paul J. , Chesdachai, Supavit , Saleh, Omar Abu , Chesdachai, Supavit , Jensen, Kelsey , Mara, Kristin C. , Yetmar, Zachary A. , Rivera, Christina G.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.679 Get It

Abstract Background Posaconazole therapeutic drug monitoring (TDM) is widely utilized to assess therapeutic efficacy and safety (i.e., hepatotoxicity, QTc prolongation); however, little is known about clinical effects of very high serum posaconazole serum levels (i.e., ≥ 5000 mg/mL). Reported incidence rate of adverse drug reactions (ADRs) with posaconazole per most recent clinical trial was ∼30%. The primary objective was to compare the ADR incidence in patients with serum posaconazole levels of 3000-4999 ng/mL to ≥5000 ng/mL. Methods This retrospective cohort study included adult patients with a posaconazole serum level ≥3000 ng/mL from 1/1/2019 to 04/30/2021. The primary outcome was symptomatic ADR at time of first serum level ≥3000 ng/mL. Secondary outcomes were laboratory defined hepatoxicity, electrolyte and adrenal laboratory abnormalities, QTc changes, and dose changes in response to TDM. Patient outcomes were censored after the first serum level and were compared between groups using Fisher’s exact tests. Results Ninety patients met inclusion criteria, 80 with a level of 3000-4999 ng/mL and 10 with a level of ≥ 5000 ng/mL occurring at a median of 91 days (26-443) and 27 days (12-45) from posaconazole initiation, respectively. Majority of patients were immunocompromised (55.6% transplant recipients, 28.9% active malignancy, 5.6% other) with a split of treatment (50%) and prophylaxis (42.2%) indication. Symptomatic ADRs were very common in patients with posaconazole levels of ≥5000 ng/mL and 3000-4999 ng/mL (80% vs. 58.8%; p=0.31), primarily neurologic (49.1% overall) followed by gastrointestinal (32.7% overall). Hepatotoxicity was also common (≥5000 ng/mL 40% vs 3000-4999 ng/mL 23.4%, p=0.26). Fifty percent of patients had the posaconazole dose continued without change. Electrolytes and QTc results were similar between groups, but median overall QTc was borderline high (456 [IQR 435, 479]). Conclusion There are safety concerns for patients with serum posaconazole levels ≥3000 ng/mL. Posaconazole levels should be monitored and, importantly, dose adjusted according to serum level and patient symptoms for both treatment and prophylaxis indications. Disclosures Christina G. Rivera, PharmD, Gilead: Grant/Research Support|Gilead: Honoraria|Insmed: Honoraria.
Time to Complete Response within 24 Months As a Good Surrogate Marker of 8 Year-Progression Free Survival in Extranodal Marginal Zone Lymphoma
Conconi, Annarita , Nowakowski, Grzegorz S. , Thiéblemont, Catherine , Bommier, Côme , Zucca, Emanuele , Cerhan, James R. , Lambert, Jérôme

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3583-3584

10.1182/blood-2022-169805 Get It

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
Parekh, Samir , Yang, David T. , Kostakoğlu, Lale , Baghdadi, Tareq Al, Maddocks, Kami J. , Romer, Mark D., Inwards, David J. , Lerner, Rachel E. , Little, Richard F. , Friedberg, Jonathan W. , Leonard, John P. , Parekh, Samir , Smith, Mitchell R. , Jegede, Opeyemi A. , Martin, Peter, Till, Brian G. , Casulo, Carla , Bartlett, Nancy L. , Caimi, Paolo F. , Wagner, Lynne I. , Kahl, Brad S.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 186-188

10.1182/blood-2022-170381 Get It

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A P
Borate, Uma , Li, Rui , Huang, Ying , Swords, Ronan , Stein, Eytan M. , Foran, James M. , Baer, Maria R. , Odenike, Olatoyosi , Patel, Prapti A. , Collins, Robert H. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Arellano, Martha , Blum, William , Schiller, Gary J. , Boyiadzis, Michael , Redner, Robert L. , Al‐Mansour, Zeina , Curran, Emily , Heerema, Nyla A. , Gana, Theophilus J. , Martycz, Molly , Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O. , Stefanos, Mona , Druggan, Franchesca , Burd, Amy , Byrd, John C. , Byrd, John C , Traer, Elie , Duong, Vu H. , Stock, Wendy , Madanat, Yazan F. , Smith, Catherine C. , Lin, Tara L. , Foster, Matthew C , Chen, Timothy Frank , Levine, Ross L. , Druker, Brian J , Mims, Alice S

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6200-6203

10.1182/blood-2022-167316 Get It